Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

from Applied Health Economics and Health Policy at http://bit.ly/2MzIB1K on August 23, 2019 at 06:54AM Abstract Background Cladribine tablets have recently become available in The Netherlands for patients with relapsing–remitting multiple sclerosis (RRMS) as a disease-modifying agent that reduces the frequency and severity of relapses and delays disability progression. Objective The aim of this study […]